MPN Advocacy and Education International is being supported in part by the following partners who have contributed to educational programs and projects for MPN patients, caregivers, and physicians. It is our goal to strengthen collaborations, provide a greater understanding of how drugs are developed and approved, and form partnerships with all of our constituents with the shared goal and purpose of providing access to information, treatments, and quality care.
Partners: Industry
Incyte
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.
Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across Oncology and Inflammation & Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For more information, visit Incyte.com and follow @Incyte.
Abbvie
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. abbvie.com
Find out if you’re eligible for navitoclax clinical trials:
PharmaEssentia Corporation, based in Taipei, Taiwan, is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today the company is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung.
PharmaEssentia recently received regulatory approval from the U.S. FDA for BESREMi (ropeginterferon alfa-2b-njft), a novel, long-acting, mono-pegylated proline interferon. It is the first interferon approved for PV worldwide and the only approved treatment for PV in the U.S. regardless of prior treatment history. For more information, visit www.pharmaessentia.com, www.pharmaessentiasource.com, or www.besremi.com, or find Pharma Essentia on LinkedIn and Twitter.
Imago BioSciences, A Subsidiary of Merck & Co.
Imago BioSciences, a subsidiary of Merck & Co., a San Francisco-based biotechnology company, is developing a novel treatment for myeloproliferative neoplasms (MPNs) targeting the enzyme lysine-specific demethylase 1 (LSD1). LSD1 is an epigenetic regulator of gene expression critical for the regulation of myelopoiesis. Inhibition of LSD1 had profound effects on the natural history of myelofibrosis and essential thrombocythemia in mouse models of those diseases. IMG-7289 is a once-daily capsule currently in a Phase 1/2 trial in Australia. www.imagobio.com
Kartos Therapeutics
Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor. Launched in 2018 by proven industry veterans, we are a passionate team based in Redwood City, California, and Bellevue, Washington. We have brought together scientists and clinicians with a deep understanding of hematology and oncology and an experienced leadership team. Together, we’re building an exciting biotechnology company with a culture defined by caring, ambition, dedication, and teamwork!
Protagonist Therapeutics
Protagonist leverages its proprietary peptide technology platform to discover and develop novel drug candidates that can transform the existing treatment paradigms in diseases with significant unmet medical needs.
PTG-300 is a mimetic of the natural hormone hepcidin that is currently in a phase 2 study in polycythemia vera (PV), a rare blood disorder, and a phase 2 study in hereditary hemochromatosis (HH), a blood disorder arising from absence or deficiency of hepcidin gene. Hepcidin is a master regulator of iron homeostasis and controls the absorption, storage, and distribution of iron in the body.
Sobi is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. Their therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers.
www.sobi.com
At Silence, we aim to transform peoples’ lives around the world by silencing diseases through our precision-engineered medicines and driving positive change for the communities around us. One area we’re working on developing a potential gene silencing therapy for is Polycythemia Vera (PV). Look out for further information about our upcoming study due to launch in the US (and beyond) before the end of 2022.